Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Roivant Sciences Ltd - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ROIV
Nasdaq
8731
http://roivant.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Roivant Sciences Ltd
Institutional investors are Roivant Sciences Ltd.'s (NASDAQ:ROIV) biggest bettors and were rewarded after last week's US$290m market cap gain
- May 5th, 2024 12:45 pm
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
- Apr 2nd, 2024 11:00 am
Stocks to Watch Wednesday: Carnival, Robinhood, Trump Media, Merck
- Mar 27th, 2024 5:55 pm
Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600
- Mar 26th, 2024 10:22 pm
Roivant Sciences Third Quarter 2024 Earnings: Beats Expectations
- Feb 14th, 2024 12:13 pm
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
- Feb 13th, 2024 12:00 pm
Roivant Sciences Ltd President & COO Eric Venker Sells 96,950 Shares
- Feb 10th, 2024 7:55 am
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
- Jan 30th, 2024 9:05 pm
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
- Dec 20th, 2023 9:30 pm
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
- Dec 14th, 2023 2:00 pm
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
- Nov 28th, 2023 12:00 pm
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
- Nov 27th, 2023 1:00 pm
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
- Nov 13th, 2023 12:00 pm
Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors
- Nov 10th, 2023 1:00 pm
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023
- Oct 30th, 2023 9:30 pm
Roche acquires Telavant, rights to bowel disease drug
- Oct 23rd, 2023 1:52 pm
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
- Oct 23rd, 2023 5:00 am
Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer
- Oct 13th, 2023 12:00 pm
Insider Sell: Eric Venker Sells 1,200,000 Shares of Roivant Sciences Ltd (ROIV)
- Oct 5th, 2023 9:01 am
Insider Sell: President & COO Eric Venker Sells 500,000 Shares of Roivant Sciences Ltd (ROIV)
- Sep 30th, 2023 9:00 am
Scroll